Henlius Receives the NMPA’s Approval for HLX03 (biosimilar, adalimumab) to Treat Autoimmune Disease

 Henlius Receives the NMPA’s Approval for HLX03 (biosimilar, adalimumab) to Treat Autoimmune Disease

Henlius Receives the NMPA’s Approval for HLX03 (biosimilar, adalimumab) to Treat Autoimmune Disease

Shots:

  • NMPA has approved HLX03 for the treatment of RA, AS and PsO. It is the first China-developed biosimilar, approved both in China and in the EU
  • The approval marks the expansion of the Henlius’ commercial pipeline into the field of autoimmune diseases and the scope of patients befitted with the therapy
  • Henlius will continue optimizing and upgrading the product, and cooperating with Wanbang Biopharma to promote the commercialization of biosimilar, to bring the high-quality treatment options to patients suffering from autoimmune diseases

Click here ­to­ read full press release/ article | Ref: Henlius | Image: Henlius

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post